Rapamycin extends murine lifespan but has limited effects on aging.

@article{Neff2013RapamycinEM,
  title={Rapamycin extends murine lifespan but has limited effects on aging.},
  author={Frauke Neff and Diana Flores-Dom{\'i}nguez and Devon Patrick Ryan and Marion Horsch and Susanne Schroeder and Thure Adler and Luciana Caminha Afonso and Juan Antonio Aguilar-Pimentel and Lore Becker and Lillian Garrett and Wolfgang Hans and Moritz M. Hettich and Richard Holtmeier and Sabine M H{\"o}lter and Kristin Moreth and Cornelia Prehn and Oliver Puk and Ildik{\'o} R{\'a}cz and Birgit Rathkolb and Jan Rozman and Beatrix Naton and Rainer Ordemann and Jerzy Adamski and Johannes Beckers and Raffi Bekeredjian and Dirk H Busch and Gerhard Ehninger and Jochen Graw and Heinz Hoefler and Martin Klingenspor and Thomas Klopstock and Markus W. Ollert and J{\"o}rg Stypmann and Eckhard Wolf and Wolfgang Wurst and Andreas Zimmer and Helmut Fuchs and Val{\'e}rie Gailus-Durner and Martin Hrabě de Angelis and Dan Ehninger},
  journal={The Journal of clinical investigation},
  year={2013},
  volume={123 8},
  pages={3272-91}
}
Aging is a major risk factor for a large number of disorders and functional impairments. Therapeutic targeting of the aging process may therefore represent an innovative strategy in the quest for novel and broadly effective treatments against age-related diseases. The recent report of lifespan extension in mice treated with the FDA-approved mTOR inhibitor rapamycin represented the first demonstration of pharmacological extension of maximal lifespan in mammals. Longevity effects of rapamycin may… CONTINUE READING